

Lexaria Bioscience Corp.

09:41 29 Sep 2020

Lexaria gets ethics board nod for human trial of DehydraTECH drug delivery system; launches rodent trial with COVID-19 drugs

Lexaria Bioscience Corp (OTCQB:LXRP) (CSE:LXX) announced Tuesday that its ethics board has approved a pilot human study evaluating the ability of its DehydraTECH drug delivery platform to boost the effectiveness of antiviral drugs being studied against coronavirus strains.

Lexaria initially announced plans for the study in March, and now that the company has the blessing of its ethics board, it will begin the process of filing for approval from federal regulators.

"We are excited at this progress towards our pilot human study using our patented DehydraTECH platform in the delivery of antiviral drugs, and are continuing the process towards regulatory approval so we can advance this important study," CEO Chris Bunka said in a statement.

READ: Lexaria Bioscience wins order commitments for 4.4M CBD servings of its patented DehydraTECH-enabled CBD powders

Lexaria also announced the launch of a separate rodent antiviral study to evaluate potential pharmacokinetic benefits of DehydraTECH in the delivery of two classes of antiviral drugs being investigated as treatments for COVID-19. Dosing of the rodents has already begun and results are expected in December, the company said.

"We are pleased to have started an animal study using DehydraTECH on certain potential COVID-19 drugs under investigation," Bunka said. "Not only will this study help to determine whether DehydraTECH is capable of delivering higher proportionate doses of the antiviral drugs than generic versions of the drugs, but the outcomes should also be beneficial in gaining regulatory approval for the planned human study."

Many antiviral drugs are fat-soluble and present bioavailability challenges in reaching the human bloodstream when taken orally, the company said. Lexaria's expertise in the oral delivery of fat-soluble drugs could improve the administration of antiviral drugs, potentially removing the need for injection treatments, which are both more costly and less comfortable, the company added.

If Lexaria's technology is proven to increase the delivery effectiveness of antiviral drugs, the company said it will make its technology available to researchers throughout the world looking to maximize the effectiveness of their own drug investigations.


Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Price: 0.255

Market Cap: \$22.96 m

1 Year Share Price Graph



November 2019 May 2020 November 20

Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	0.75	0.22

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).